340B Drug Pricing Program
We’re 11 days into 2019 … we’ve returned to a divided government …and the partial government shutdown continues.
AHA commends the Centers for Medicare & Medicaid Services' willingness to address excessive growth in drug prices, but urges CMS to consider narrowing the scope of the program.
A federal judge today ruled in favor of the AHA and hospital plaintiffs saying that the Department of Health and Human Services “adjustment” by nearly 30 percent of 2018 Medicare payment rates for many hospitals in the 340B Drug Pricing Program was unlawful.
Dec. 27, 2018 court decision in 340B payment case
As urged by the AHA, the Health Resources and Services Administration today announced that it expects to publish online by April 1 drug ceiling prices under the 340B Drug Pricing Program.
The Department of Health and Human Services today issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
The Department of Health and Human Services today issued a final rule making Jan. 1 the effective date of its final regulations on drug ceiling prices and civil monetary penalties for manufacturers under the 340B Drug Pricing Program.
Tom Nickels
Executive Vice President
As the industry “that generates higher profit margins than any other,” Big Pharma continues to price gouge consumers for life-saving drugs. One thing the pharmaceutical industry is not entitled to, however, is its own set of facts.